EBITDA margin expansion from 9% to 14% (+500 bps) driven by aggressive cost reduction manufacturing restructuring (external to internal), energy cost reduction, and wastage elimination shows operating discipline alongside the R&D investment
Evidence also shows that when people stop taking GLP-1s, weight regain is common, raising the risk of worsening health over time
Medicare begins coverage of GLP-1 medications for obesity July 7, 2026 Summary: Starting July 1, 2026, Medicare beneficiaries can access GLP-1 obesity drugs for a flat $50 monthly copay through the CMS Bridge demonstration, an 18-month, taxpayer-funded stopgap created after private insurers balked at the original BALANCE model
The patients who feel 10 years younger didnt find a miracle
If you are looking at the ozempic cost without insurance or the wegovy cost without insurance to lose weight without surgery you have probably seen two things: the prices are very high